During the past decade, Louisville Oncology conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 3 clinical trials were completed, i.e. on average, 150% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Louisville Oncology" #1 sponsor was "EMD Serono" with 1 trials, followed by "Hoffmann-La Roche" with 1 trials sponsored, "Millennium Pharmaceuticals, Inc." with 1 trials sponsored, "Novartis Pharmaceuticals" with 1 trials sponsored and "Seagen Inc." with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Louisville Oncology" #1 collaborator was "Belgian Gynaecological Oncology Group" with 1 trials as a collaborator, "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 1 trials as a collaborator, "Genmab" with 1 trials as a collaborator, "Gynecologic Oncology Group" with 1 trials as a collaborator and "Johnson & Johnson Pharmaceutical Research & Development, L.L.C." with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Louisville Oncology" are "Ovarian Cancer" (2 trials), "Cervical Cancer" (1 trials), "Fallopian Tube Cancer" (1 trials), "Lung Cancer" (1 trials) and "Non Small Cell Lung Carcinoma" (1 trials). Many other conditions were trialed in "Louisville Oncology" in a lesser frequency.

Most popular intervention types in "Louisville Oncology" are "Drug" (6 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody" (1 trials), "Bortezomib + Rituximab" (1 trials), "Carboplatin" (1 trials), "EPO906 (Patupilone)" (1 trials) and "Etoposide" (1 trials). Other intervention names were less common.

The vast majority of trials in "Louisville Oncology" are 3 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Louisville Oncology". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Louisville Oncology, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Louisville Oncology, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".